» Articles » PMID: 38995003

Hypoxia Promotes Invadosome Formation by Lung Fibroblasts

Overview
Journal Cells
Publisher MDPI
Date 2024 Jul 12
PMID 38995003
Authors
Affiliations
Soon will be listed here.
Abstract

Lung parenchymal hypoxia has emerged as a cardinal feature of idiopathic pulmonary fibrosis (IPF). Hypoxia promotes cancer cell invasion and metastasis through signaling that is dependent upon the lysophosphatidic acid (LPA) receptor, LPA (LPAR1). Abundant data indicate that LPA-dependent signaling also enhances lung fibrogenesis in IPF. We recently reported that fibroblasts isolated from the lungs of individuals with IPF have an increased capacity to form subcellular matrix-degradative structures known as invadosomes, an event that correlates with the degree of lung fibrosis. We therefore hypothesized that hypoxia promotes invadosome formation in lung fibroblasts through LPA-dependent signaling. Here, it is demonstrated that invadosome formation by fibroblasts from the lungs of individuals with advanced IPF is inhibited by both the tyrosine receptor kinase inhibitor nintedanib and inhibition of LPA. In addition, exposure of normal human lung fibroblasts to either hypoxia or LPA increased their ability to form invadosomes. Mechanistically, the hypoxia-induced invadosome formation by lung fibroblasts was found to involve LPA and PDGFR-Akt signaling. We concluded that hypoxia increases the formation of invadosomes in lung fibroblasts through the LPA and PDGFR-Akt signaling axis, which represents a potential target for suppressing lung fibrosis.

References
1.
Takai M, Takauchi M, Kuribayashi M, Tsujiuchi T . LPA receptor-mediated signaling regulates cell motility and survival to anticancer drug of pancreatic cancer cells under glucose-deprived and hypoxic conditions. Biochem Biophys Res Commun. 2023; 661:21-27. DOI: 10.1016/j.bbrc.2023.04.036. View

2.
Kim J, Park S, Park S, Choi J, Xia Y, Sung J . The pivotal role of reactive oxygen species generation in the hypoxia-induced stimulation of adipose-derived stem cells. Stem Cells Dev. 2011; 20(10):1753-61. PMC: 3182032. DOI: 10.1089/scd.2010.0469. View

3.
Palmer S, Snyder L, Todd J, Soule B, Christian R, Anstrom K . Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018; 154(5):1061-1069. DOI: 10.1016/j.chest.2018.08.1058. View

4.
Shea B, Tager A . Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc. 2012; 9(3):102-10. PMC: 5455616. DOI: 10.1513/pats.201201-005AW. View

5.
Mikami Y, Grubb B, Rogers T, Dang H, Asakura T, Kota P . Chronic airway epithelial hypoxia exacerbates injury in muco-obstructive lung disease through mucus hyperconcentration. Sci Transl Med. 2023; 15(699):eabo7728. PMC: 10664029. DOI: 10.1126/scitranslmed.abo7728. View